Karyopharm Therapeutics Inc. (KPTI)
NASDAQ: KPTI · Real-Time Price · USD
0.6050
+0.0050 (0.83%)
At close: Oct 9, 2026, 4:00 PM EDT
0.6000
-0.0050 (-0.83%)
After-hours: Oct 9, 2026, 7:57 PM EDT
Karyopharm Therapeutics Revenue
Karyopharm Therapeutics had revenue of $33.43M in the quarter ending June 30, 2026, a decrease of -11.86%. This brings the company's revenue in the last twelve months to $146.62M, up 6.81% year-over-year. In the year 2025, Karyopharm Therapeutics had annual revenue of $146.07M with 0.57% growth. That makes Karyopharm Therapeutics the 19,771st largest company in the world by revenue and 3,074th in the United States.
Revenue (ttm)
$146.62M
Revenue Growth
+6.81%
P/S Ratio
0.09
Revenue / Employee
$643,075
Employees
228
Market Cap
13.72M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 146.07M | 830.00K | 0.57% |
| Dec 31, 2024 | 145.24M | -796.00K | -0.55% |
| Dec 31, 2023 | 146.03M | -11.04M | -7.03% |
| Dec 31, 2022 | 157.07M | -52.75M | -25.14% |
| Dec 31, 2021 | 209.82M | 101.73M | 94.12% |
| Dec 31, 2020 | 108.09M | 67.19M | 164.31% |
| Dec 31, 2019 | 40.89M | 10.56M | 34.80% |
| Dec 31, 2018 | 30.34M | 28.73M | 1,790.09% |
| Dec 31, 2017 | 1.61M | 1.45M | 942.21% |
| Dec 31, 2016 | 154.00K | -96.00K | -38.40% |
| Dec 31, 2015 | 250.00K | 21.00K | 9.17% |
| Dec 31, 2014 | 229.00K | -158.00K | -40.83% |
| Dec 31, 2013 | 387.00K | -247.00K | -38.96% |
| Dec 31, 2012 | 634.00K | 482.00K | 317.11% |
| Dec 31, 2011 | 152.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
KPTI News
- 10 days ago - Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 4 weeks ago - Karyopharm, guarantors enter into forbearance agreement - TheFly
- 5 weeks ago - Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 5 weeks ago - Karyopharm submits sNDA to FDA for XPOVIO - TheFly
- 5 weeks ago - Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - PRNewsWire
- 7 weeks ago - Karyopharm reports Q2 EPS ($2.32) vs. ($4.32) last year - TheFly
- 1 month ago - Karyopharm Therapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 1 month ago - Karyopharm Therapeutics Earnings release: Q2 2026 - Filings